Editas Medicine, Inc. (EDIT)

Market Cap	686.94M
Revenue (ttm)	25.64M
Net Income (ttm)	-201.13M
Shares Out	68.76M
EPS (ttm)	-2.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	476,768
Open	10.30
Previous Close	9.89
Day's Range	9.78 - 10.30
52-Week Range	7.71 - 21.60
Beta	1.87
Analysts	Hold
Price Target	15.75 (+57.66%)
Earnings Date	Feb 23, 2023

About EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 3, 2016
• Employees: 264
• Stock Exchange: NASDAQ
• Ticker Symbol: EDIT

Financial Performance

In 2021, EDIT's revenue was $25.54 million, a decrease of -71.85% compared to the previous year's $90.73 million. Losses were -$192.50 million, 66.0% more than in 2020.

Analyst Forecast

According to 25 analysts, the average rating for EDIT stock is "Hold." The 12-month stock price forecast is $15.75, which is an increase of 57.66% from the latest price.

Price Target

$15.75

(57.66% upside)

Analyst Consensus: Hold